ReviewNanomedicine (London, England)2010
Engineering nanomedicines for improved melanoma therapy: progress and promises.
Review in Nanomedicine (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 97 citations in OpenAlex.
- Phytosomes against melanoma: disrupting molecular pathways with targeted phytochemical delivery.Discover nano · 2026Review
- Nanotechnology in Cutaneous Oncology: The Role of Liposomes in Targeted Melanoma Therapy.Molecules (Basel, Switzerland) · 2026Review
- Multiple Strategies for the Application of Medicinal Plant-Derived Bioactive Compounds in Controlling Microbial Biofilm and Virulence Properties.Antibiotics (Basel, Switzerland) · 2025Review
- Nanozyme-Engineered Hydrogels for Anti-Inflammation and Skin Regeneration.Nano-micro letters · 2024Review
- Nanotechnology-Based Drug Delivery Systems in the Transdermal Treatment of Melanoma.Advanced pharmaceutical bulletin · 2023Review
- Unraveling the nature of nano-diamonds and silica in a catheterized tapered artery: highlights into hydrophilic traits.Scientific reports · 2023Article
- Functional nano-systems for transdermal drug delivery and skin therapy.Nanoscale advances · 2023Review
- Nanoemulgel: A Novel Nano Carrier as a Tool for Topical Drug Delivery.Pharmaceutics · 2023Review
- Polymeric Nanocapsules Containing Fennel Essential Oil: Their Preparation, Physicochemical Characterization, Stability over Time and in Simulated Gastrointestinal Conditions.Pharmaceutics · 2022Article
- Phenotypic, functional, and metabolic heterogeneity of immune cells infiltrating non-small cell lung cancer.Frontiers in immunology · 2022Review
- Nanoparticle-Based Combination Therapy for Melanoma.Frontiers in oncology · 2022Review
- Recent Advances in Nanotechnology for the Treatment of Melanoma.Molecules (Basel, Switzerland) · 2021Review
- New insights on the role of autophagy in the pathogenesis and treatment of melanoma.Molecular biology reports · 2020Review
- Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future.Purinergic signalling · 2019Review
- Carnosic acid impedes cell growth and enhances anticancer effects of carmustine and lomustine in melanoma.Bioscience reports · 2018Article
- Cubic liquid crystalline nanoparticles containing a polysaccharideSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2018Article
- Bacterial-Derived Polymer Poly-y-Glutamic Acid (y-PGA)-Based Micro/Nanoparticles as a Delivery System for Antimicrobials and Other Biomedical Applications.International journal of molecular sciences · 2017Review
- Anticancer Activities of Surfactin and Potential Application of Nanotechnology Assisted Surfactin Delivery.Frontiers in pharmacology · 2017Review
- Cationic PEGylated polycaprolactone nanoparticles carrying post-operation docetaxel for glioma treatment.Beilstein journal of nanotechnology · 2017Article
- Novel therapeutic mechanisms determine the effectiveness of lipid-core nanocapsules on melanoma models.International journal of nanomedicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Once metastatic, melanoma remains one of the most aggressive and morbid malignancies. Moreover, in past decades, the overall survival for advanced unresectable melanoma exhibited a constancy of poor prognosis. Low response rates and serious adverse effects have been characteristic of standard therapy based on a combination of chemotherapeutic agents or immunotherapy with IL-2. For example, the chemotherapy including dacarbazine, carmustin, cisplatin and tamoxifen is known as 'Dartmouth regimen' while the CVD regimen comprises carmustine, vinblastine and dacarbazine. Thus, there is an urgent and critical need to reformulate these bioactive agents using nanoscience and nanotechnology as alternative strategies. This article overviews current design and evaluation of nanomedicine undertaken to address this unmet medical need. The nanomedicines studied include polymeric nanoparticles, liposomes, polymersomes, dendrimers, cubosomes, niosomes and nanodiamonds. In this preclinical article, nanotechnology provides hope for effective treatment of this aggressive and largely treatment-resistant disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.